Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Intercontinental Exchange and RELX are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...

Generic drugmaker Granules India is foraying into the peptide segment and contract development and manufacturing organisation (CDMO) business with a ₹192.5 crore (CHF 20 million) acquisition of Swiss ...

Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...